--- config: sankey: showValues: false linkColor: target width: 800 height: 1000 nodeAlignment: right --- sankey-beta exome, 2012 exome studies, 64 2012 exome studies, Richter 2012, 5 2012 exome studies, Love 2012, 59 Richter 2012, Tier 1 BL genes, 5 Love 2012, Tier 1 BL genes, 3 Love 2012, Tier 2 BL genes, 56 RNA-seq, 2012 RNA-seq studies, 19 2012 RNA-seq studies, Schmitz 2012, 19 Schmitz 2012, BL Tier 1, 3 Schmitz 2012, BL Tier 2, 16 RNA-seq/exome, RNA-seq/exome studies,47 RNA-seq/exome studies, Panea 2019, 47 Panea 2019, Tier 2 BL genes, 43 Panea 2019, Tier 1 BL genes, 4 WGS,2019 WGS studies,13 2019 WGS studies, Grande 2019, 13 Grande 2019, Tier 1 BL genes, 8 Grande 2019, Tier 2 BL genes, 5 Panel, 2022 panel studies, 25 2022 panel studies, Burkhardt 2022, 25 Burkhardt 2022, Tier 2 BL genes, 25 WGS, 2023 WGS studies, 3 2023 WGS studies, Thomas 2023, 3 Thomas 2023, Tier 2 BL genes, 1 Thomas 2023, Tier 1 BL genes, 2

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.